Lipocalin-2 (LCN2) hormone suppresses food intake and increase satiety

Lipocalin-2 (LCN2) hormone could be used as a potential treatment in people with obesity whose natural signals for feeling full no longer work, after researchers found that it can suppress food intake and increase the feeling of fullness in mice and has shown similar results in humans and non-human primates. The outcomes were reported in the paper, ‘Lipocalin-2 is an anorexigenic signal in primates’, published in eLife.

Remission of obesity-related complications after adolescent bariatric surgery

Eighty to 90% of adolescents benefit from lasting weight loss following bariatric surgery and most experience the remission of obesity-related complications such as elevated blood pressure, high cholesterol, type 2 diabetes and musculoskeletal pain, among others, according to researchers from Children's Hospital Colorado (Children's Colorado).

Bariatric surgery may reduce COVID-19 severity in patients with obesity

A Cleveland Clinic study has reported that among patients who have obesity and who tested positive for COVID-19, a past history of bariatric surgery was significantly associated with a lower risk of hospital and intensive care unit admission. The results of the study, ‘Association of prior metabolic and bariatric surgery with severity of coronavirus disease 2019 (COVID-19) in patients with obesity’, were published in the journal of Surgery for Obesity and Related Diseases.